Göttingen, 20.02.2024: A lot will change for us soon. More information coming soon.

Goettingen, Germany, March 4, 2022 - With Jörn Tolstrup, PhD we strengthen our team. He joins Curexsys to be responsible for all clinical operations starting with the company's first [...]

As the first company, alongside the Life Science Factory team, we moved to the new Sartorius quarter on Weender Landstrasse on January 1st, 2022. We are enthusiastic about the [...]

- Strengthened management team headed by Jörg Neermann as CEO  Goettingen, Germany, October 20, 2021 - Curexsys GmbH, a leader in the emerging field of therapeutic exosomes, today announced [...]

Curexsys acquires a family of patents (EP2195430 & EP 3199633, US8729038 & US9951329, CA2699638, JP2010538625) enabling both targeted delivery of therapeutics and transfer of multiple therapeutic modalities including small [...]

Curexsys researchers contribute to two studies that will be presented at the annual meeting of the European Society for Cell and Gene Therapy (ESGCT 2021). Both have been performed [...]

Göttingen, Germany, May 1, 2021 – Curexsys GmbH, a new, pre-clinical stage therapeutic company developing iMSC derived exosomes for age-related diseases and anti-aging therapies, announced the appointment of Dr [...]

Göttingen, Germany, April 1, 2021 – Curexsys GmbH, a new, pre-clinical stage therapeutic company developing iMSC derived exosomes for age-related diseases and anti-aging therapies, announced that Dr Michael Shalmi [...]

Evotec and Sartorius partner with Start-Up Curexsys on iPSC-based therapeutic exosome approach. Download Press Release